Nishida Takahiro, Tominaga Ryuji
Department of Cardiovascular Surgery, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Gen Thorac Cardiovasc Surg. 2013 Apr;61(4):182-90. doi: 10.1007/s11748-013-0202-z. Epub 2013 Jan 24.
The various uses of biological valves for either aortic or mitral valve replacement have recently increased because of the growing proportion of elderly patients requiring surgery.
The durability of recent xenografts has been reported to be over 90 % at 10 years after aortic or mitral valve replacement for elderly patients more than 65 years of age, and therefore the guidelines now recommend the use of bioprostheses for patients over 65 years of age. Bioprostheses are also recommended for valve replacement of the right side of the heart by several authors; however, no clear guidelines are available. Trans-catheter aortic valve replacement and percutaneous pulmonary valve implantation are promising procedures for high-risk patients, although evaluation of the long-term durability of these valves is mandatory.
This article will review the development of the tissue valve for valve surgery.
由于需要手术的老年患者比例不断增加，生物瓣膜在主动脉瓣或二尖瓣置换中的各种应用近来有所增加。
据报道，对于65岁以上的老年患者，在进行主动脉瓣或二尖瓣置换术后10年，近期异种移植物的耐久性超过90%，因此目前的指南推荐65岁以上的患者使用生物假体。几位作者也推荐使用生物假体进行心脏右侧瓣膜置换；然而，尚无明确的指南。经导管主动脉瓣置换术和经皮肺动脉瓣植入术对于高危患者是有前景的手术，尽管必须评估这些瓣膜的长期耐久性。
本文将综述瓣膜手术组织瓣膜的发展。
